[Leu31,Pro34]-Neuropeptide Y (porcine)Cat. No. 1168 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Alternative Name: [Leu31 , Pro34]-NPY (porcine) |
Biological Activity
High affinity neuropeptide Y Y1 receptor agonist (Ki = 0.54 nM). Also shows affinity for Y5 receptors.Technical Data
M.Wt:(Modifications: Tyr-36 = C-terminal amide)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
References
Fuhlendorff et al (1990) [Leu31, Pro34]Neuropeptide Y: a specific Y1 receptor agonist. Proc.Natl.Acad.Sci.U.S.A. 87 182. PMID: 2153286.
Bard et al (1995) Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY. J.Biol.Chem. 270 26762. PMID: 7592911.
Kask et al (1998) Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: studies with Y1-selective antagonist BIBP3226. Br.J.Pharmacol. 124 1507. PMID: 9723965.
Michel et al (1998) XVI.International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol.Rev. 50 143. PMID: 9549761.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: [Leu31,Pro34]-Neuropeptide Y (porcine), supplier, NPY, Y1, receptor, agonist, Neuropeptide, Y, Receptors, [Leu31Pro34]-NeuropeptideY, (porcine), neuropeptides
Quick Order
Find multiple products by catalog number
New Products in this Area
Oxytocin analog
ML 221Apelin receptor (APJ) antagonist
Q94 hydrochlorideNegative allosteric modulator at PAR1 receptor
FSLLRY-NH2PAR2 peptide antagonist
SB 611812Urotensin-II (UT) antagonist; attenuates cardiac dysfunction
TC-MCH 7cSelective melanin-concentrating hormone receptor 1 (MCH1R) antagonist
CYM 9484Potent NPY Y2 receptor antagonist
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.







